Michele Moschetta

7.0k total citations · 1 hit paper
96 papers, 4.2k citations indexed

About

Michele Moschetta is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Michele Moschetta has authored 96 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 44 papers in Molecular Biology and 36 papers in Hematology. Recurrent topics in Michele Moschetta's work include Multiple Myeloma Research and Treatments (36 papers), Ovarian cancer diagnosis and treatment (15 papers) and Chemokine receptors and signaling (14 papers). Michele Moschetta is often cited by papers focused on Multiple Myeloma Research and Treatments (36 papers), Ovarian cancer diagnosis and treatment (15 papers) and Chemokine receptors and signaling (14 papers). Michele Moschetta collaborates with scholars based in United States, United Kingdom and Italy. Michele Moschetta's co-authors include Stergios Boussios, Aldo M. Roccaro, Irene M. Ghobrial, Elie Rassy, Nicholas Pavlidis, Angelo Vacca, Salomon Manier, Matin Sheriff, Siobhan Glavey and Yuji Mishima and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Cancer Research.

In The Last Decade

Michele Moschetta

95 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4

2024 52 citations Aruni Ghose, Elisabet Sanchez et al. profile →

Peers

Countries citing papers authored by Michele Moschetta

Since Specialization

Citations

This map shows the geographic impact of Michele Moschetta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele Moschetta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele Moschetta more than expected).

Fields of papers citing papers by Michele Moschetta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michele Moschetta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele Moschetta. The network helps show where Michele Moschetta may publish in the future.

Co-authorship network of co-authors of Michele Moschetta

This figure shows the co-authorship network connecting the top 25 collaborators of Michele Moschetta. A scholar is included among the top collaborators of Michele Moschetta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michele Moschetta. Michele Moschetta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic Factors in Patients with Metastatic Spinal Cord Compression Secondary to Lung Cancer—A Retrospective UK Single-Centre Study 2023 ·Cancers ·(unknown), (unknown), (unknown), (unknown), Afroditi Karathanasi, Aruni Ghose, Matin Sheriff, Christos Mikropoulos, Elisabet Sanchez, Michele Moschetta, Cyrus Chargari, Elie Rassy, Stergios Boussios	1
2	A View on Drug Development for Cancer Prevention 2023 ·Cancer Discovery ·Andrew R. Reynolds, Michele Moschetta, (unknown), Farzana L. Walcott, Marianne Ashford, Zoltán Szűcs, (unknown), James Hadfield, (unknown), Benjamin Challis, (unknown), Gaia Schiavon, Caroline Germa, (unknown), (unknown), Susan Galbraith	11
3	719TiP A phase I/Ib study of the Werner (WRN) helicase inhibitor HRO761 as single agent and in combination with irinotecan or tislelizumab in patients with microsatellite instability-high (MSIhi) or mismatch repair deficient (dMMR) advanced solid tumors 2023 ·Annals of Oncology ·Michele Moschetta, Toshihiko Doi, Yasutoshi Kuboki, Raghav Sundar, Henrik Möbitz, Isabel Jaco, (unknown), Stéphane Ferretti, (unknown), (unknown), Giuseppe Clementi, (unknown), Ruben de Kanter, Cornelia Quadt	1
4	Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence 2023 ·Annals of Palliative Medicine ·Mario Uccello, Sola Adeleke, Michele Moschetta, Aruni Ghose, Stergios Boussios	9
5	Unraveling the Wide Spectrum of Melanoma Biomarkers 2021 ·Diagnostics ·(unknown), Sidrah Shah, (unknown), Michele Moschetta, Mehmet Akif Öztürk, George Pappas‐Gogos, Evangelia Ioannidou, Matin Sheriff, Elie Rassy, Stergios Boussios	60
6	Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition 2021 ·Molecular Cancer Therapeutics ·Larissa S. Carnevalli, Molly A. Taylor, Matthew King, Anna Coenen-Stass, Adina Hughes, (unknown), Theresa A. Proia, Yanjun Wang, Antonio Ramos‐Montoya, Neha Wali, Danielle Carroll, Maneesh Singh, Michele Moschetta, Pablo Morentin Gutierrez, Cristina Gardelli, Susan E. Critchlow, Teresa Klinowska, Stephen E. Fawell, Simon T. Barry	14
7	Progression signature underlies clonal evolution and dissemination of multiple myeloma 2020 ·Blood ·Yu J. Shen, Yuji Mishima, Jiantao Shi, Romanos Sklavenitis‐Pistofidis, Robert Redd, Michele Moschetta, Salomon Manier, Aldo M. Roccaro, Antonio Sacco, Yu‐Tzu Tai, François Mercier, Yawara Kawano, Nang Kham Su, Brianna Berrios, John G. Doench, David E. Root, Franziska Michor, David T. Scadden, Irene M. Ghobrial	32
8	Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets—a narrative review 2020 ·Annals of Translational Medicine ·Eleftherios Pierre Samartzis, Sana Intidhar Labidi‐Galy, Michele Moschetta, Mario Uccello, Dimitrios Rafail Kalaitzopoulos, José Alejandro Pérez Fidalgo, Stergios Boussios	49
9	Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab 2018 ·Molecular Cancer Therapeutics ·Ahmed T. Kurdi, Siobhan Glavey, Natalie Bezman, (unknown), Jennifer L. Guerriero, Salomon Manier, Michele Moschetta, Yuji Mishima, Aldo M. Roccaro, Alexandre Detappe, Chia‐Jen Liu, Antonio Sacco, Daisy Huynh, Yu‐Tzu Tai, Michael Robbins, Jamil Azzi, Irene M. Ghobrial	70
10	Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation 2018 ·Clinical Cancer Research ·Satoshi Takagi, Shokichi Tsukamoto, Jihye Park, Kelly E. Johnson, Yawara Kawano, Michele Moschetta, Chia‐Jen Liu, Yuji Mishima, Katsutoshi Kokubun, Salomon Manier, Karma Z. Salem, Daisy Huynh, Antonio Sacco, (unknown), Aldo M. Roccaro, Elisabeth M. Battinelli, Irene M. Ghobrial	45
11	Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer 2017 ·Experimental Hematology and Oncology ·Michele Moschetta, Gabriel Mak, (unknown), (unknown), Mario Uccello, Hendrik‐Tobias Arkenau	9
12	Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model 2016 ·Cancer Research ·Antonio Sacco, Aldo M. Roccaro, Dong-Dong Ma, Jiantao Shi, Yuji Mishima, Michele Moschetta, Marco Chiarini, Nikhil C. Munshi, Robert I. Handin, Irene M. Ghobrial	41
13	Dynamics of neutrophil to lymphocyte ratio (NLR) predict effectiveness of PD1/PDL1 inhibition 2016 ·Annals of Oncology ·Michele Moschetta, Benjamin Kasenda, Gabriel Mak, Mark Voskoboynik, (unknown), Saeed Rafii, Vincenzo Formica, Hendrik‐Tobias Arkenau	2
14	Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma 2015 ·Cancer Research ·Patricia Maiso, Daisy Huynh, Michele Moschetta, Antonio Sacco, Yosra Aljawai, Yuji Mishima, John M. Asara, Aldo M. Roccaro, Alec C. Kimmelman, Irene M. Ghobrial	166
15	A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target 2014 ·Clinical Cancer Research ·(unknown), Michele Moschetta, Maria Antonia Frassanito, Simona Berardi, Ivana Catacchio, Roberto Ria, Vito Racanelli, Antonella Caivano, Antonio Giovanni Solimando, Daniele Vergara, Michele Maffia, Dominga Latorre, Antonia Rizzello, Alfredo Zito, Paolo Ditonno, Eugenio Maiorano, Doménico Ribatti, Angelo Vacca	53
16	HIF-1α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target 2013 ·Clinical Cancer Research ·Roberto Ria, Ivana Catacchio, Simona Berardi, Annunziata De Luisi, Antonella Caivano, Cláudia Piccoli, Vitalba Ruggieri, Maria Antonia Frassanito, Doménico Ribatti, Beatrice Nico, Tiziana Annese, Simona Ruggieri, Attilio Guarini, Carla Minoia, Paolo Ditonno, Emanuele Angelucci, Daniele Derudas, Michele Moschetta, Franco Dammacco, Angelo Vacca	50
17	Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma 2013 ·Clinical Cancer Research ·Michele Moschetta, Antonio Basile, (unknown), Maria Antonia Frassanito, Luigia Rao, Roberto Ria, Antonio Giovanni Solimando, Nicola Giuliani, Angelina Boccarelli, Fabio Fumarola, Mauro Coluccia, (unknown), Simona Ruggieri, Beatrice Nico, Eugenio Maiorano, Doménico Ribatti, Aldo M. Roccaro, Angelo Vacca	54
18	Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectin–Positive Metastatic Human Melanoma Xenografts 2012 ·Cancer Research ·Michele Moschetta, Francesca Pretto, Alexander Berndt, Kerstin M. Galler, Petra Richter, Andrea Bassi, Paolo Oliva, Edoardo Micotti, Giovanni Valbusa, Kathrin Schwager, Manuela Kaspar, Eveline Trachsel, Hartwig Kosmehl, Maria Rosa Bani, Dario Neri, Raffaella Giavazzi	78
19	Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross‐talk in the bone marrow of multiple myeloma patients 2012 ·The Journal of Pathology ·(unknown), Michele Moschetta, Paolo Ditonno, Roberto Ria, (unknown), Annunziata De Luisi, Simona Berardi, Maria Antonia Frassanito, Emanuele Angelucci, Daniele Derudas, Giorgina Specchia, Paola Curci, Vincenzo Pavone, (unknown), Doménico Ribatti, Barbara Bottazzi, Alberto Mantovani, Marco Presta, Franco Dammacco, Angelo Vacca	31
20	Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma 2009 ·European Journal of Cancer ·Michele Moschetta, Giulia Di Pietro, Roberto Ria, Antonio Gnoni, Giuseppe Mangialardi, Attilio Guarini, Paolo Ditonno, Pellegrino Musto, Fiorella D’Auria, Maria Rosaria Ricciardi, Franco Dammacco, Doménico Ribatti, Angelo Vacca	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact